SBR00057
Retapamulin
≥98% (HPLC)
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C30H47NO4S
CAS Number:
Molecular Weight:
517.76
UNSPSC Code:
51284706
NACRES:
NA.76
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
antibiotic activity spectrum
Gram-positive bacteria
mode of action
protein synthesis | interferes
storage temp.
−20°C
SMILES string
S(C4C[C@@H]5N([C@@H](CC5)C4)C)CC(=O)O[C@H]1[C@]2([C@H]3[C@@]([C@H]([C@@H]([C@](C1)(C)C=C)O)C)(CC[C@H]2C)CCC3=O)C
InChI
1S/C30H47NO4S/c1-7-28(4)16-24(35-25(33)17-36-22-14-20-8-9-21(15-22)31(20)6)29(5)18(2)10-12-30(19(3)27(28)34)13-11-23(32)26(29)30/h7,18-22,24,26-27,34H,1,8-17H2,2-6H3/t18-,19+,20-,21+,22?,24-,26+,27+,28-,29+,30+/m1/s1
InChI key
STZYTFJPGGDRJD-FJJJPKKESA-N
General description
Retapamulin (RET) is a semi-synthetic antibiotic ointment, and pleuromutilin derivative compound. The primary structural difference between pleuromutilin and retapamulin is in the C-14 side chain.
Biochem/physiol Actions
Retapamulin is a potent antibacterial agent against Gram-positive bacteria, especially against Staphylococcus aureus and S. pyogenes. It displays synergistic effects against Enterococcus faecalis in combination with streptogramin (MLS). RET initiates ribosomal arrests at the start codon and enables genes to use alternative translational sites in E. coli.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
In vitro synergistic effect of retapamulin with erythromycin and quinupristin against Enterococcus faecalis
Park B, et al
The Journal of Antibiotics, 73, 630-635 (2020)
Retapamulin-Assisted Ribosome Profiling Reveals the Alternative Bacterial Proteome
Meydan S, et al
Molecular Cell, 74, 481-493 (2019)
Retapamulin: Current Status and Future Perspectives
Goudarzi M, et al
Archives of Clinical Infectious Diseases, 16, 4-4 (2021)
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SBR00057-50MG | 04065268909874 |